Vx147    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
222一次性ネフローゼ症候群2

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000185-42-FR
(EUCTR)
12/06/202026/05/2020Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. APOL1-mediated Focal segmental glomerulosclerosis (FSGS)
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX-147
Product Code: VX-147
INN or Proposed INN: VX147
Other descriptive name: VX-147
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2United States;France;United Kingdom
2EUCTR2020-000185-42-GB
(EUCTR)
01/06/202023/03/2020Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. APOL1-mediated Focal segmental glomerulosclerosis (FSGS)
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX-147
Product Code: VX-147
INN or Proposed INN: VX147
Other descriptive name: VX-147
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2France;United States;United Kingdom